Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.

Cancer Cell. 2017; 
Mahajan Kiran,Malla Pavani,Lawrence Harshani R,Chen Zhihua,Kumar-Sinha Chandan,Malik Rohit,Shukla Sudhanshu,Kim Jongphil,Coppola Domenico,Lawrence Nicholas J,Mahajan Nup
Products/Services Used Details Operation
Polyclonal Antibody Services polyclonal antibody Genscript Cat#A01176-40; RRID: AB_1237588 RNA Pol II Active Motif Cat#61667 IgG Get A Quote

摘要

The androgen receptor (AR) is critical for the progression of prostate cancer to a castration-resistant (CRPC) state. AR antagonists are ineffective due to their inability to repress the expression of AR or its splice variant, AR-V7. Here, we report that the tyrosine kinase ACK1 (TNK2) phosphorylates histone H4 at tyrosine 88 upstream of the AR transcription start site. The WDR5/MLL2 complex reads the H4-Y88-phosphorylation marks and deposits the transcriptionally activating H3K4-trimethyl marks promoting AR transcription. Reversal of the pY88-H4 epigenetic marks by the ACK1 inhibitor (R)-9bMS-sensitized naive and enzalutamide-resistant prostate cancer cells and reduced AR and AR-V7 levels to mitigate CRPC ... More

关键词

ACK1,AR,AR-V7,TNK2,castration resistance,enzalutamide,epigenetics,histone,prostate cancer,small-molecule inhibitor,tyrosine phosphoryla
XML 地图